Indaptus Therapeutics (INDP) Action Cours

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focused on curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens, with its lead candidate Decoy20 in pre-clinical development. Its platform uses a multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) delivered intravenously via attenuated and killed non-pathogenic bacteria to activate both innate and adaptive cellular immunity in tumors and immune organs. The company's intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in immune organs and sites common for primary and metastatic cancer and hepatitis B virus (HBV) infection. The company's business model centers on developing its proprietary immunotherapy platform and lead candidate Decoy20 for potential future commercialization. As a pre-clinical stage biotech, Indaptus does not yet generate revenue from product sales but relies on funding from investors and potential future partnerships. The target market includes patients with unresectable or metastatic solid tumors and lymphomas, as well as those with hepatitis B virus (HBV) infection who may benefit from the immune activation properties of its therapeutic candidates. Indaptus Therapeutics' primary revenue stream will come from licensing its technology and therapeutic candidates to pharmaceutical companies for further development and commercialization. The company's focus on targeting specific antigens and its unique bacterial-based platform position it for potential partnerships with major pharmaceutical firms seeking innovative cancer immunotherapy solutions. The pre-clinical nature of its lead candidate Decoy20 indicates that the company is still in the research and development phase, with potential future revenue dependent on successful clinical trials and regulatory approvals.